【摘要】：目的:本研究意在觀察溫陽(yáng)復(fù)元方對(duì)缺血性中風(fēng)恢復(fù)期的臨床綜合療效及其對(duì)S-100B蛋白、神經(jīng)肽Y、超敏C-反應(yīng)蛋白的影響,以明確其療效,并初步探討其療效機(jī)制,并為其臨床應(yīng)用打下堅(jiān)實(shí)的基礎(chǔ)。方法:選擇符合缺血性中風(fēng)恢復(fù)期診斷標(biāo)準(zhǔn)的患者80例,采取區(qū)組隨機(jī)的原則分為治療組(溫陽(yáng)復(fù)元方+西醫(yī)常規(guī)治療,簡(jiǎn)稱溫陽(yáng)復(fù)元方組)、對(duì)照組(補(bǔ)陽(yáng)還五湯+西醫(yī)常規(guī)治療,簡(jiǎn)稱補(bǔ)陽(yáng)還五湯組)各40例。治療前及治療4周后進(jìn)行臨床綜合療效以及實(shí)驗(yàn)室指標(biāo)(S-100B蛋白、神經(jīng)肽Y、超敏C-反應(yīng)蛋白)評(píng)定,并前后進(jìn)行統(tǒng)計(jì)學(xué)分析。結(jié)果:(1)、兩組臨床綜合療效比較:治療組37例,基本痊愈7例,顯效17例,有效10例,無(wú)效3例,總有效率91.89%;對(duì)照組36例,基本痊愈4例,顯效12例,有效10例,無(wú)效10例,總有效率72.22%;兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05),表明溫陽(yáng)復(fù)元方組效果優(yōu)于補(bǔ)陽(yáng)還五湯組。(2)、兩組S-100B蛋白(S-100B protein)比較:兩組患者治療前血清中S-100B的含量比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后對(duì)比,兩組之間存在差異性(P0.05),表明溫陽(yáng)復(fù)元方組下調(diào)S-100B的效果優(yōu)于補(bǔ)陽(yáng)還五湯組。(3)、兩組神經(jīng)肽Y(Neuropeptide Y,NPY)比較:兩組患者治療前血漿中NPY的含量比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后對(duì)比,兩組之間存在差異性(P0.05),表明溫陽(yáng)復(fù)元方組下調(diào)血漿NPY的效果優(yōu)于補(bǔ)陽(yáng)還五湯組。(4)、兩組超敏C-反應(yīng)蛋白(high-sensitivity C-reactive protein,hs-CRP)比較:兩組患者治療前血清中hs-CRP的含量比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后對(duì)比,兩組之間存在差異性(P0.05),表明溫陽(yáng)復(fù)元方組下調(diào)血清hs-CRP的效果優(yōu)于補(bǔ)陽(yáng)還五湯組。結(jié)論:溫陽(yáng)復(fù)元方聯(lián)合西醫(yī)常規(guī)療法治療缺血性中風(fēng)恢復(fù)期療效優(yōu)于補(bǔ)陽(yáng)還五湯聯(lián)合西醫(yī)常規(guī)療法,初步揭示了溫陽(yáng)復(fù)元方的作用機(jī)制可能與下調(diào)S-100B、NPY、hs-CRP含量表達(dá)有關(guān)。
[Abstract]:Objective: To study the effect of Wenyang Fuyuan on the recovery of ischemic stroke and its effect on S-100B protein, neuropeptide Y and hypersensitive C-reactive protein. Methods: 80 patients with ischemic stroke recovery criteria were selected, and the random principle of the group was divided into treatment group (Wenyang Fuyuan + Western medicine general treatment, hereinafter referred to as" Wenyang Fuyuan "group), and the control group (Bu Yang, Wu Tang + Western medicine). 40 cases of each of the five decoction groups. The clinical comprehensive curative effect and the laboratory index (S-100B protein, neuropeptide Y and hypersensitive C-reactive protein) were evaluated before and after treatment for 4 weeks, and the statistical analysis was performed before and after treatment. Results: (1) In the treatment group, 37 cases were cured, 7 cases were cured, 17 cases were effective, 10 cases were effective, 3 cases were ineffective, the total effective rate was 91.89%, 36 cases in the control group, 4 cases were basically cured, 12 cases were effective, 10 cases were effective, and the total effective rate was 72.22%. The difference of the two groups was statistically significant (P <0.05), indicating that the effect of the Wenyang Fuyuan group was superior to that of the Wuyang Huanwu Decoction group. (2) The S-100B protein in the two groups was compared with that of S-100B protein in the two groups (P0.05). There was a difference between the two groups (P0.05). (3) There was no significant difference between the two groups of neuropeptide Y (NPY). There was no significant difference between the two groups (P0.05). There was a difference between the two groups after the treatment (P0.05). (4) The high-sensitivity C-reactive protein (hs-CRP) in the two groups showed no significant difference in the levels of hs-CRP in the two groups (P0.05). The results showed that the effect of reducing serum hs-CRP in Wenyang Fuyuan group was superior to that of the Wuyang Huanwu decoction group. Conclusion: The curative effect of Wenyang Fu-yuan combined with western medicine in the treatment of ischemic stroke is superior to that of the traditional Chinese medicine for the treatment of ischemic stroke. It is suggested that the mechanism of warming Yang Fu-yuan is related to the down-regulation of the content of S-100B, NPY, hs-CRP.
【學(xué)位授予單位】：廣西中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R743.3

【參考文獻(xiàn)】

中國(guó)期刊全文數(shù)據(jù)庫(kù) 前10條

1 黃家俊;杜林;汪永強(qiáng);王衛(wèi);;炎性因子與急性腦梗死多因素的相關(guān)性研究[J];華西醫(yī)學(xué);2016年12期

2 陳堅(jiān);;急性腦血管病患者血漿神經(jīng)肽Y和神經(jīng)降壓素水平的測(cè)定與分析[J];中國(guó)實(shí)用神經(jīng)疾病雜志;2016年19期

3 楊鵬飛;宋修云;陳乃宏;;三七總皂苷抗腦缺血再灌注損傷的藥理研究進(jìn)展[J];藥學(xué)學(xué)報(bào);2016年07期

4 白玉娟;李琦軍;周紅艷;李炎;張國(guó)亮;;神經(jīng)肽Y對(duì)大鼠皮質(zhì)神經(jīng)元凋亡的調(diào)節(jié)作用研究[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2016年10期

5 王成太;;益氣活血法治療缺血性腦卒中恢復(fù)期患者的臨床療效及對(duì)hs-CRP、Fg、HCY水平的影響[J];實(shí)用臨床醫(yī)藥雜志;2016年03期

6 楊鵬飛;楚世峰;陳乃宏;;黨參的藥理學(xué)研究進(jìn)展及其抗腦缺血再灌注損傷的機(jī)制[J];湖南中醫(yī)藥大學(xué)學(xué)報(bào);2015年12期

7 朱紅霞;肖曉華;易本誼;;益氣消栓顆粒結(jié)合針灸治療老年氣虛血瘀型缺血性腦卒中恢復(fù)期老年患者肌力障礙的療效及機(jī)制[J];中國(guó)老年學(xué)雜志;2015年23期

8 王健;陳晶;譚峰;;從血脈理論對(duì)缺血性中風(fēng)的論治[J];遼寧中醫(yī)雜志;2015年11期

9 謝佳宏;楊志新;韓淑麗;;補(bǔ)陽(yáng)還五湯治療缺血性腦卒中恢復(fù)期的系統(tǒng)評(píng)價(jià)[J];中醫(yī)藥導(dǎo)報(bào);2015年20期

10 沈顯群;龔自力;;血清高遷移率族蛋白B1白細(xì)胞介素-18和-23 S100B及同型半胱氨酸和神經(jīng)肽Y水平檢測(cè)對(duì)缺血性腦卒中預(yù)后的影響[J];中國(guó)實(shí)用神經(jīng)疾病雜志;2015年19期

中國(guó)碩士學(xué)位論文全文數(shù)據(jù)庫(kù) 前1條

1 朱海榮;淫羊藿苷保護(hù)缺血性腦損傷及其分子機(jī)制[D];南京中醫(yī)藥大學(xué);2010年

，

本文編號(hào)：2425992